Motor neuron disease due to neuropathy target esterase gene mutation: Clinical features of the index families by Rainier, Shirley et al.
MOTOR NEURON DISEASE DUE TO NEUROPATHY TARGET ESTERASE
GENE MUTATION: CLINICAL FEATURES OF THE INDEX FAMILIES
SHIRLEY RAINIER, PhD,1 JAMES W. ALBERS, MD, PhD,1 PETER J. DYCK, MD,2 O. PETTER ELDEVIK, MD, PhD,3
SANDRA WILCOCK, RN,1 RUDY J. RICHARDSON, ScD,1,4 and JOHN K. FINK, MD1,5
1Department of Neurology, University of Michigan, 5013 BSRB, 109 Zina Pitcher Place, Ann Arbor, Michigan 48109, USA
2Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
3Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
4Toxicology Research Training Program, Department of Environmental Health Sciences, University of Michigan,
Ann Arbor, Michigan, USA
5Geriatric Research, Education, and Clinical Center, Veterans Affairs Medical Center, Ann Arbor, Michigan, USA
Accepted 27 April 2010
ABSTRACT: Recently, we reported that mutations in the neu-
ropathy target esterase (NTE) gene cause autosomal recessive
motor neuron disease (NTE-MND). We describe clinical, neuro-
physiologic, and neuroimaging features of affected subjects in
the index families. NTE-MND subjects exhibited progressive
lower extremity spastic weakness that began in childhood and
was later associated with atrophy of distal leg and intrinsic
hand muscles. NTE-MND resembles Troyer syndrome, except
that short stature, cognitive impairment, and dysmorphic fea-
tures, which often accompany Troyer syndrome, are not fea-
tures of NTE-MND. Early onset, symmetry, and slow
progression distinguish NTE-MND from typical amyotrophic lat-
eral sclerosis. NTE is implicated in organophosphorus com-
pound–induced delayed neurotoxicity (OPIDN). NTE-MND
patients have upper and lower motor neuron deficits that are
similar to OPIDN. Motor neuron degeneration in subjects with
NTE mutations supports the role of NTE and its biochemical
cascade in the molecular pathogenesis of OPIDN and possibly
other degenerative neurologic disorders.
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We recently reported the discovery of neuropathy
target esterase (NTE) gene mutations in a consan-
guineous family (family 1, Fig. 1A) and a non-con-
sanguineous family (family 2, Fig. 1B) in which
affected subjects exhibited slowly progressive spas-
tic paraplegia and distal muscle atrophy.1 Herein
we provide a detailed description of the clinical
features1 and results of electrodiagnostic and neu-
roimaging studies of affected subjects in these
families.
METHODS
We examined 7 members of a consanguineous
South American kindred of Ashkenazi Jewish
descent (Fig. 1) and 5 members of a non-consan-
guineous Caucasian family of German ancestry.
Participation in this study was approved by the
institutional review board at the University of
Michigan.
Sensory and motor nerve conduction studies
were performed in the dominant upper and lower
extremities of subject 2 using standard percutane-
ous nerve stimulation and surface recordings. Sen-
sory and motor response amplitudes and latencies
were measured and conduction velocities were cal-
culated. F-response latencies were obtained for
motor nerves. Skin temperatures were maintained
between 32.0 and 34.0C. Neuromuscular trans-
mission was evaluated by repetitive stimulation (2
HZ) of the median and ulnar motor nerves before
and after brief volitional exercise. Concentric nee-
dle electromyography (EMG) was performed on
selected proximal and distal muscles of the upper
and lower extremities, and insertional activity and
motor unit potential recruitment and configura-
tion were evaluated.
Brain magnetic resonance imaging (MRI) and
cervical and thoracic spine MRI were performed in
subject 2 without intravenous gadolinium using a
1.5-Tesla scanner. Axial T1, axial T2, and sagittal
T2 sequences obtained of the brain, and sagittal
T1, sagittal T2, and axial T2 sequences were
obtained of the cervical and thoracic spine.
Quantitative sensation testing (QST) of the
hand and foot was performed in subject 2 using
CASE III or IV (WR Medical Electronics, Stillwater,
Minnesota).
RESULTS
Clinical Descriptions. Clinical findings and results
of diagnostic studies are summarized in Table 1.
Antenatal and perinatal histories (available from
the parents of subjects 2, 3, and 4) were unremark-
able, and developmental milestones were attained
normally. Each subject had a slowly progressive
gait disturbance that began in early childhood
(subject 1) around age 4 years (subjects 2 and 4)
or around age 7 years (subject 3). Progressive
weakness and atrophy in the hands became evident
in the late teenage years (subjects 1 and 2),
between age 12 and 21 years (subject 3), or
around age 20 years (subject 4). Each subject
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reported urinary urgency beginning in adulthood.
Subjects did not report cognitive impairment, vis-
ual disturbance, swallowing difficulties, sensory
loss, or symptoms of autonomic disturbance such
as postural light-headedness or impaired sweating.
Subject 1 had mild dysarthria dating to early adult-
hood that was slowly progressive.
Neurologic examinations were performed at 82
(subject 1), 48 (subject 3), and 34 (subject 4) years
of age. Subject 2 was examined six times between
ages, 8 and 35 years.
Each subject exhibited marked atrophy and
weakness of intrinsic muscles of the hands (most
notably in the thenar group and dorsal interossei)
and distal lower extremities. Although intrinsic
hand muscles were markedly weak, strength was
preserved in wrist extensors, wrist flexors, and prox-
imal upper extremity muscles. Subject 4 had ham-
string muscle contractures. Other subjects had mod-
erate to marked spasticity in hamstring muscles,
moderate to marked weakness of iliopsoas
muscles, and marked weakness of tibialis anterior
muscles. Upper extremity deep tendon reflexes were
brisk (3þ) in subjects 1, 2, and 3, but they were
diminished in subject 4. Deep tendon reflexes at the
knees were hyperactive in subjects 1, 2, and 4, but
FIGURE 1. (A) NTE-MND syndrome families (modified from Rainier et al.1). (B) Distal atrophy in NTE-MND syndrome.
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they were absent in subject 4. Ankle jerks were dimin-
ished (subjects 2 and 3) or absent (subjects 1 and 4).
All subjects exhibited extensor plantar responses. Vi-
bratory sensation was diminished in the toes. Light
touch and pinprick sensations were normal in sub-
jects 3 and 4, but were diminished distally in subject
1 (who was examined at 82 years of age).
There was moderate to severe functional
impairment that was generally similar between the
two families. Subject 1 was unable to walk (when
examined at age 82) because of severe lower ex-
tremity spasticity, weakness, and hamstring tendon
contractures. His niece (subject 2, age 38 years)
had prominent spastic gait and scissoring but was
ambulatory without assistance. There was some evi-
dence of intrafamily variation. Whereas subject 4
had marked spastic paraparesis and was marginally
ambulatory even with a walker at 38 years of age,
Table 1. Clinical features and diagnostic studies of NTE-MND subjects.




Unavailable Unremarkable Unremarkable Unremarkable
Age of onset of
slowly progressive
gait disturbance
Early childhood 4 years 7 years 4 years
Age of onset of
weakness and atrophy
in the hands
Teenage years Teenage years Teenage years 20 years
Age of onset of
urinary urgency
Adulthood Adulthood Adulthood Adulthood
Age at neurologic
examination
82 years Serial exams
ages 8–35 years



















Marked Moderate Moderate Marked
Deep tendon reflexes 3þ UE and
knees; absent
ankle DTRs
3þ UE and knees; 2þ
ankle DTRs
3þ UE and knees;
markedly diminished
ankle DTRs
3þ UE and knees;
markedly diminished
ankle DTRs
Plantar response Extensor Extensor Extensor Extensor
Light touch and
pin-prick sensation
Diminished Normal Normal Normal
Distal vibration
sensation
Reduced Reduced Reduced Reduced





















muscles and later distal
upper extremity and proximal
lower extremity muscles








Not available MRI (age 30 years): normal
brain; significant thoracic
spinal cord atrophy
Not available Not available
DTR, deep tendon reflex; EMG, electromyography; MRI, magnetic resonance imaging; NCS, nerve conduction studies; UE, upper extremities.
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his older sister (age 48) had moderate spastic para-
paresis, but was fully ambulatory with a four-
pronged cane.
Serial evaluations of subject 2 at age 8, 11, 12,
17, 20, and 35 years disclosed an evolving pheno-
type. Initial examination (age 8 years) and subse-
quent examinations showed a spastic gait that
worsened progressively. Lower extremity hyperre-
flexia and extensor plantar responses were present
from the initial evaluation (age 8). Tendon
reflexes in the upper extremities were normal, and
corticobulbar signs were absent at each evaluation.
Although examinations through 17 years of age
showed normal upper extremity strength, examina-
tions at ages 20 and 35 years showed definite weak-
ness and atrophy of thenar, hypothenar, and inter-
osseous muscles. These muscles were markedly
weak at the last examination (age 35 years). Quan-
titative sensation testing (performed in the hand
and foot using CASE III or IV (WR Medical Elec-
tronics, Stillwater, Minnesota) was performed on
each occasion and was normal until the last exami-
nation (age 35 years), when decreased vibration
was detected at the great toe and index finger.
Neurophysiologic and Neuroimaging Studies and
Muscle Biopsy. Motor nerve conduction studies
(NCSs) and needle EMG were normal in subject 4
when they were performed at age 4 years. Motor
NCSs performed in subject 3 at age 12.5 years
showed decreased amplitude ulnar, median, and
peroneal motor responses and a slightly increased
median motor distal latency. Sensory NCSs were
normal. EMG findings (subject 3, age 12.5 years)
were interpreted as showing neurogenic atrophy in
distal muscles. For example, there was markedly
decreased motor unit potential recruitment, large-
amplitude and long-duration motor unit poten-
tials, increased insertional activity, and 2þ fibrilla-
tion potentials in the first dorsal interosseous mus-
cle. EMG of the tibialis anterior demonstrated a
‘‘mixed population’’ of large and small motor unit
potentials.
Serial nerve conduction studies in subject 2 at
age 8, 11, 12, 17, and 20 years documented pro-
gressive motor neuropathy or neuronopathy. Pero-
neal and tibial compound muscle action potential
(CMAP) amplitudes were already reduced at 8
years of age (0.8 and 1.6 mV, respectively), further
reduced by age 12 (0.5 and 0.3 mV, respectively),
and absent at age 20. The ulnar CMAP amplitude
was 4.2 mV at 8 years of age (normal value >6.0
mV). This borderline-low amplitude decreased pro-
gressively (3.6, 2.2, and 0.7 mV at age 11, 12, and
20 years, respectively).
NCSs performed in subject 2 at age 30 years
showed normal sensory studies, including a normal
sural sensory nerve action potential. Median and
ulnar CMAP amplitudes were markedly reduced
(0.3 and 2.5 mV, respectively), and peroneal and
tibial CMAPs were unobtainable. The median
motor distal latency was slightly prolonged, and
the conduction velocity was reduced to a degree
consistent with loss of large motor axons. There
was no evidence of motor conduction block or
abnormal temporal dispersion. The ulnar motor
distal latency and conduction velocity were normal,
as was the F-wave latency. There was no evidence
of impaired neuromuscular transmission. Needle
EMG at 30 years of age showed chronic distal par-
tial denervation and reinnervation characterized by
small-amplitude fibrillation potentials (some mi-
nute) and decreased recruitment of large-ampli-
tude motor unit potentials. True myotonic dis-
charges were recorded from a single fibrotic
muscle (anterior tibialis), which also showed severe
neurogenic changes. The study was interpreted as
showing evidence of a moderately severe motor
neuronopathy characterized by clinically symmetric
distal involvement. The myotonic discharges
recorded from a single fibrotic muscle were noted
to be a non-specific finding associated on occasion
with chronic denervation.
Serial needle EMG examinations showed evolu-
tion of this chronic dennervation. Whereas exami-
nation at age 8 years showed slightly increased
insertional activity, fibrillation potentials, and
decreased recruitment characterized by large poly-
phasic motor unit potentials only in the intrinsic
foot muscles, examination at age 11 showed
increased insertional activity, fasciculation poten-
tials, and alteration of motor unit potentials
(increased size and duration) in distal lower ex-
tremity muscles. At 20 years of age, these abnor-
malities included the anterior tibial muscle. At
35 years of age, intrinsic hand muscles were simi-
larly affected, and very mild but similar changes
were found in anterior thigh muscles.
Muscle biopsy obtained from the extensor digi-
torum communis muscle of subject 3 at age
12 years of age was judged to be ‘‘non-diagnostic.’’
There was no significant histologic evidence of
chronic denervation despite EMG findings from
the first dorsal interosseous, tibialis anterior, and
adductor digiti quinti muscles that were consistent
with chronic denervation at this age.
Magnetic resonance imaging of the brain and
spinal cord were performed in subject 2 (Fig. 2).
No significant intracranial abnormality was identi-
fied with appropriate cerebellar and midbrain vol-
umes, and there was no evidence of corpus cal-
losum atrophy or agenesis. MRI of the spinal cord
showed significant cord atrophy beginning at the
T3–4 level and extending down to T11, where the
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cord expanded at the conus medullaris (Fig. 3).
Thoracic spinal cord cross-sectional area2 at T9 was
reduced (25 mm2) compared with control subjects
(39.3 6 8.1 mm2). There was no evidence of
intrinsic spinal cord signal aberration, compres-
sion, or significant narrowing of the central canal.
DISCUSSION
The salient features of subjects with NTE-MND
are: (1) childhood onset of slowly progressive spas-
tic paraplegia; (2) progressive atrophy of intrinsic
muscles of the hands and distal lower extremities
beginning in early through late adolescence; (3)
mild diminution of distal vibration sensation; and
(4) family history consistent with autosomal reces-
sive inheritance. EMG and nerve conduction stud-
ies were consistent with progressive motor nerve
impairment. Peripheral sensory nerve studies were
normal. Neuroimaging identified prominent tho-
racic spinal cord atrophy in the one patient
studied.
NTE-MND may be classified as a form of hered-
itary spastic paraplegia (designated SPG39).1 Dur-
ing childhood and early adolescence, NTE-MND
presents as an ‘‘uncomplicated’’ hereditary spastic
paraplegia (HSP) syndrome. The subsequent
appearance (in early through late adolescence) of
progressive atrophy of distal upper and lower ex-
tremity muscles signals transition to a complicated
HSP syndrome involving both upper and lower
motor neurons. Such lower motor neuron signs
occur as a constant or variable feature in many
forms of complicated HSP (SPG7, SPG10, SPG14,
SPG15, SPG17, SPG20, and SPG26 HSP; see Fink3
for review), and in SPG3A,4,5 a common childhood-
onset form of HSP that is usually uncomplicated.
Among the various forms of HSP, NTE-MND
most closely resembles SPG20 HSP (Troyer syn-
drome), a complicated form of autosomal recessive
HSP that was initially described in Old Order
Amish due to SPG20/spartin gene mutation.6,7
Although both Troyer syndrome and NTE-MND
have progressive spastic paraplegia and distal mus-
cle atrophy, it is notable that many subjects with
the SPG20/spartin mutation have neurologic signs
that are not present in the SPG39/NTE-mutation
subjects identified to date. In addition to progres-
sive spastic paraplegia, subjects with SPG20/spartin
mutation have delayed milestones (15 of 21 exam-
ined subjects), cognitive impairment (in 17 of
21 examined subjects), emotional lability (in 17 of
21 subjects), cerebellar signs (16 of 21 examined
subjects), spastic dysarthria (19 of 21 examined sub-
jects), skeletal abnormalities (all 21 examined sub-
jects), ataxia (3 of 17 examined subjects), choreoa-
thetoid movements (3 of 21 examined subjects),
and dysphagia (2 of 21 examined subjects).8 More-
over, 3 of 21 subjects with SPG20/spartin mutation
did not have distal muscle atrophy, indicating that
clinical diagnosis cannot rest on this major feature
FIGURE 2. MRI of brain and spinal cord in NTE-NMD syndrome. (A) No significant intracranial abnormality is identified. The corpus
callosum (not shown here) was present without evidence of atrophy. Significant spinal cord atrophy is present beginning at the T3–4
level where the cord again expands at the conus medullaris. Although atrophic, the spinal cord was not compressed, and there were
no spinal cord aberrations. (B) Cord transverse area (circle) at T9 measured 25 mm2 at the T9 level (compared with control subjects,
not shown) that measure 39.3 6 8.1 mm2.
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alone. Our observations suggest that the presence
or absence of these additional signs (cognitive, bul-
bar, cerebellar, emotional, and extrapyramidal def-
icits and skeletal abnormalities) help distinguish
SPG20/spartin-mutation/Troyer syndrome subjects
from those with NTE mutations.
The NTE-MND subjects just described were
ascertained as familial clusters suggesting autoso-
mal recessive inheritance. Because subjects with
autosomal recessive disorders often have no previ-
ous family history of the disorder, it is possible
that NTE mutations contribute to motor neuron
disease among subjects without a family history of
the disease.
NTE is an important factor in OPIDN,9–14 a dis-
tal axonopathy that, like NTE-MND, is character-
ized in late-stage disease by spastic paraparesis with
distal weakness and atrophy. Causes of OPIDN
include occupational and accidental exposures to
neuropathic organophosphorus compounds.15–20
One example of OPIDN is a disorder sometimes
referred to as ‘‘jake leg palsy,’’ in reference to the
accompanying ingestion of Jamaican ginger
(‘‘jake’’) and to the characteristic gait displayed by
afflicted individuals reflecting a combination of
upper and lower motor neuron involvement. The
disorder may have affected as many as 50,000 indi-
viduals in the Prohibition-era United States. Jake
leg palsy was attributed to recreational con-
sumption of Jamaican ginger extract, a patent
medicine adulterated with tri-ortho-cresyl phosphate
(TOCP).21 In addition to the clinical similarity
between OPIDN and NTE-MND, neuropathologic
findings in the chicken model of OPIDN (includ-
ing axon degeneration of corticospinal tracts and
dorsal column fibers)13 overlap the predominant
localization of neurologic signs in subjects with
NTE-MND mutation. These observations suggest
that motor neuron syndrome associated with the
organophosphorus compound–NTE interaction
shares a common molecular pathogenesis with
motor neuron disease attributed to homozygous
(or compound heterozygous)1 NTE mutations.
This observation supports the hypothesis that some
apparently sporadic (or genetically occult) MNDs
could be due to exposure to some neuropathic
organophosphorus compounds, either alone or to-
gether with predisposing NTE gene mutations or
genetic variation in factors that regulate or interact
with NTE.
The molecular mechanisms by which NTE dis-
turbance (both due to mutations in the NTE ester-
ase domain as well as irreversible organophosphor-
ylation of the NTE active site serine) lead to axon
degeneration that particularly involves central and
peripheral motor neurons are not clear. Recently,
we showed that the mutations in NTE-MND sub-
jects reduce NTE activity and alter its enzyme
kinetics in vitro.22 It is unknown, however, if reduc-
tion in phospholipase activity of NTE is sufficient
to cause neurodegeneration in NTE-MND. The
impact of NTE-MND mutations (and irreversible
organophosphorylation) on other emerging NTE
functions has not been assessed. Specifically, there
is recent evidence that the NTE Drosophila homo-
log Swiss Cheese (SWS) binds to and regulates
cyclic AMP-dependent protein kinase (PKA).23 Dis-
covering that human NTE regulates PKA in a simi-
lar manner would suggest additional mechanisms
(including altered phosphorylation of target pro-
teins and/or cAMP-regulated gene expression) by
which NTE disturbance leads to neurodegenera-
tion. It is also possible that NTE-mediated motor
neuron degeneration is due to NTE protein mis-
folding. Abnormal protein folding is a mechanism
common to many neurodegenerative disorders,24
including Parkinson disease,25 polyglutamine-expan-
sion disorders,26 and amyotrophic lateral sclero-
sis.27,28 Increased recognition of NTE-MND and elu-
cidating its molecular pathogenesis will provide
insight into possible gene–environment interactions
that contribute to motor neuron disease and
advance our ability to treat these disorders.
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